Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Pediatric Hematologic Malignancies
Interventions
DEVICE

Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus

Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER